22 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. Only 23 people have searched for CMPS on MarketBeat in the last 30 days. COMPASS Pathways has only been the subject of 3 research reports in the past 90 days. Join thousands of traders who make more informed decisions with our premium features.

• 29.80% of the stock of Compass Therapeutics is held by insiders.
• In addition to the simple moving average , traders also use another type of moving average called the exponential moving average .
• And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
• This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
• In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
• In the past three months, Compass Therapeutics insiders have bought more of their company’s stock than they have sold.

After a stumble in the https://1investing.in/ that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.21% of loss for the given period. Oppenheimer gave a rating of “Outperform” to CMPS, setting the target price at $50 in the report published on October 29th of the previous year. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics.

Related News CMPS

Compass Pathways stock was originally listed at a price of $29.00 in Sep 18, 2020. If you had invested in Compass Pathways stock at $29.00, your return over the last 2 years would have been -63.62%, for an annualized return of -39.68% . Traders also like to use the RSI and Fibonacci retracement level indicators to try and ascertain the future direction of the COMPASS Pathways plc stock price. COMPASS Pathways plc stock traders use a variety of tools to make a prediction on which way the CMPS market is likely to head next. These tools can roughly be divided into indicators and chart patterns. Bloomberg Markets European Close Bloomberg Markets European Close.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

Compass Pathways, GH Research Among Top Psychedelic Movers Of Today

Several pharmaceutical companies are now investigating their potential therapeutic value. Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowada… Get the hottest stocks to trade every day before the market opens 100% free.

View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

Psychedelic Stock Gainers And Losers From March 29, 2023

COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki… At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

Live from New York and London, analyzing the major can i sell a stock immediately moving stories across the day in Europe, hear from the biggest newsmakers and showcase the unrivaled expertise of Bloomberg News. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Compass Therapeutics is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 54.27% of the stock of Compass Therapeutics is held by institutions.

JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk.

Users should not base their investment decision upon StockInvest.us. By using the site you agree and are held liable for your own investment decisions and agree to the Terms of Use and Privacy Policy.Please read the full disclaimer here. A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. Let’s use a 1-hour candlestick chart as an example of how this type of price chart gives us information about opening and closing prices.

Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report), with a price target of $10.00. H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report) today and set a price target of $10.00. The company’s shares opened today at $5.17.According to TipRanks, Pa… The company’s shares opened today at $5.03.Pantginis covers the Heal… The company’s shares opened today at $3.76.Pantginis covers the Heal…

COMPASS Pathways plc announced that it has received $80 million in funding from a group of investors

U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). The incredible healing properties of psychedelics are being discovered with every passing day.

No information, materials, services and other content provided on this page constitute solicitation, recommendation, endorsement or any financial, investment, or other advice. Seek independent professional consultation in the form of legal, financial, and fiscal advice before making any investment decision. Based on the average yearly growth of the COMPASS Pathways plc stock in the last 10 years, the COMPASS Pathways plc stock forecast for the beginning of next year is $ 9.46. Using the same basis, here is the COMPASS Pathways plc stock prediction for each year up until 2030. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.

We have 9 different ratings for every stock to help you appreciate its future potential. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business.

When autocomplete results are available use up and down arrows to review and enter to select. Business Of Sports If the only thing you know about sports is who wins and who loses, you are missing the highest stakes action of all. The business owners that power this multibillion dollar industry are changing, and a new era of the business of sports is underway. From media and technology to finance and real estate, leagues and teams across the globe have matured into far more than just back page entertainment. And the decisions they make have huge consequences, not just for the bottom line, but for communities, cities, even entire countries.

Short interest in Compass Therapeutics has recently increased by 17.68%, indicating that investor sentiment is decreasing significantly. COMPASS Pathways plc reported Q4 EPS of ($0.73), $0.11 worse than the analyst estimate of ($0.62). Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes.